Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of Modified Release Tacrolimus (FK506E) in Transplant Recipients
NCT02118896Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2003
- Primary completion
- Oct 2009
- Modality
- Orthosteric Ligands
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of tacrolimus + Wuzhi capsule in heart transplant rejection, Liver transplant rejection and kidney transplant rejection, sponsored by Astellas Pharma. Primary endpoints: Participant Survival at 5.5 years and Graft Survival at 5.5 years. Started Feb 2003; status: completed.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
heart transplant rejectionLiver transplant rejectionkidney transplant rejection
Beyond the preview
Go deeper on NCT02118896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02118896.